Journal of Carcinogenesis & Mutagenesis

Simon Mahoney

Publications

• Research Article
  The Effects of Combination Treatment Using Phenoxodiol and Docetaxel, and Phenoxodiol and Secreted Frizzled-related Protein 4 on Prostate Cancer Cell Lines
  Author(s): Simon Mahoney, Frank Arfuso, Michael Millward and Arun DharmarajanSimon Mahoney, Frank Arfuso, Michael Millward and Arun Dharmarajan
  
  Although much progress has been made for the treatment of prostate cancer, patients with advanced prostate cancer still have a poor 5 year survival rate. Current practices for hormone-refractory/castrate resistant, metastatic prostate cancer involve the use of taxanes. Docetaxel, in particular, is being incorporated in numerous current clinical trials either as a single or combination agent against androgen-independent prostate cancer. Combination therapies have the potential to increase the effectiveness of drug treatments while simultaneously increasing quality of life by reducing side effects, lowering effective dosage rates, or by increasing effectiveness of one compound once combined with another. Using three diverse human prostate cancer cell lines, LNCap, DU145, and PC3, we studied the effect of the novel prostate cancer drug phenoxodiol in combination with docetaxel by utilizi.. View More»
  DOI: 10.4172/2157-2518.1000204

  Abstract PDF